logo

For the Inventor, By the Inventor

Dartmouth, Canada

Immunovaccine Technologies Inc.


USPTO Granted Patents = 20



Trademarks = 4

Forward Citations = 112

Loading Chart...
Loading Chart...

29 inventors (with patents filed for the assignee):

goldMedal Marc Mansour (15 out of 16 patents)

silverMedal Genevieve Mary Weir (12 out of 12 patents)

bronzeMedal Leeladhar Sammatur (7 out of 8 patents)

4.  Robert George Brown (7 out of 10 patents)

5.  Marianne Michelle Stanford (6 out of 6 patents)

6.  Bill Pohajdak (6 out of 11 patents)

7.  Lisa Diana MacDonald (5 out of 6 patents)

8.  Mohan Karkada (4 out of 4 patents)

9.  Warwick Charles Kimmins (4 out of 6 patents)

10.  Rajkannan Rajagopalan (3 out of 4 patents)

11.  Frederic Ors (2 out of 7 patents)

12.  Kendall Sharp (2 out of 2 patents)

13.  Jordan David Lewicky (2 out of 2 patents)

14.  Zi-hua Jiang (2 out of 3 patents)

15.  Neil L Berinstein (2 out of 12 patents)


20 patents:

1. 11717563 - Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance (2023-08-08),
2. 11406705 - Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects (2022-08-09),
3. 11260116 - Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof (2022-03-01),
4. 11235069 - Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo (2022-02-01),
5. 11160861 - Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant (2021-11-02),
6. 11077184 - Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response (2021-08-03),
7. 10988500 - Lipid A mimics, methods of preparation, and uses thereof (2021-04-27),
8. 10729766 - Method for improving the efficacy of a survivin vaccine in the treatment of cancer (2020-08-04),
9. 10533033 - Lipid A mimics, methods of preparation, and uses thereof (2020-01-14),
10. 10272042 - Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment (2019-04-30),
11. 10232052 - Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo (2019-03-19),
12. 10105435 - Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof (2018-10-23),
13. 10022441 - Method for improving the efficacy of a survivin vaccine in the treatment of cancer (2018-07-17),
14. 9925142 - Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment (2018-03-27),
15. 9498493 - Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo (2016-11-22),
IMV Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing next-generation immunotherapies for the treatment of a wide range of diseases including cancer. Through its proprietary DepoVax™ platform, IMV has developed a novel delivery technology that enables the targeted delivery of immune-activating agents to specific cells in the body. The company's lead candidate, DPX-Survivac, is being evaluated in multiple Phase 2 clinical trials for the treatment of ovarian cancer, as well as other solid tumors. IMV Inc. is headquartered in Halifax, Nova Scotia, Canada.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
20 Patents

#2 in Dartmouth

#683 in Canada

#30,316 in the World

...
Dartmouth, Canada

Immunovaccine Technologies Inc.

Forward Citations = 112

29 inventors:

goldMedal Marc Mansour (15 out of 16 patents)

silverMedal Genevieve Mary Weir (12 out of 12 patents)

bronzeMedal Leeladhar Sammatur (7 out of 8 patents)

4.  Robert George Brown (7 out of 10 patents)

5.  Marianne Michelle Stanford (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com
Loading…